DE69735090D1 - Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer'schen krankheit und schmerzen - Google Patents

Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer'schen krankheit und schmerzen

Info

Publication number
DE69735090D1
DE69735090D1 DE69735090T DE69735090T DE69735090D1 DE 69735090 D1 DE69735090 D1 DE 69735090D1 DE 69735090 T DE69735090 T DE 69735090T DE 69735090 T DE69735090 T DE 69735090T DE 69735090 D1 DE69735090 D1 DE 69735090D1
Authority
DE
Germany
Prior art keywords
loweralkyl
carboxy
optionally substituted
neurotrophine
epilepsia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69735090T
Other languages
English (en)
Other versions
DE69735090T2 (de
Inventor
Ashok Tehim
Xiannong Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NPS Allelix Corp Canada
Original Assignee
NPS Allelix Corp Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621902.7A external-priority patent/GB9621902D0/en
Priority claimed from GBGB9710904.5A external-priority patent/GB9710904D0/en
Application filed by NPS Allelix Corp Canada filed Critical NPS Allelix Corp Canada
Application granted granted Critical
Publication of DE69735090D1 publication Critical patent/DE69735090D1/de
Publication of DE69735090T2 publication Critical patent/DE69735090T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/14Aza-phenalenes, e.g. 1,8-naphthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69735090T 1996-10-21 1997-10-20 Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer'schen krankheit und schmerzen Expired - Fee Related DE69735090T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9621902.7A GB9621902D0 (en) 1996-10-21 1996-10-21 Neurotrophin antagonist compositions
GB9621902 1996-10-21
GB9710904 1997-05-27
GBGB9710904.5A GB9710904D0 (en) 1997-05-27 1997-05-27 Neurotropin antagonist compositions
PCT/CA1997/000779 WO1998017278A1 (en) 1996-10-21 1997-10-20 Neurotrophin antagonist compositions

Publications (2)

Publication Number Publication Date
DE69735090D1 true DE69735090D1 (de) 2006-04-06
DE69735090T2 DE69735090T2 (de) 2006-09-14

Family

ID=26310264

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735090T Expired - Fee Related DE69735090T2 (de) 1996-10-21 1997-10-20 Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer'schen krankheit und schmerzen

Country Status (14)

Country Link
US (4) US20020169182A1 (de)
EP (1) EP0930883B1 (de)
JP (1) JP2001503397A (de)
KR (1) KR20000052691A (de)
AT (1) ATE315397T1 (de)
AU (1) AU728523C (de)
BR (1) BR9712424A (de)
CA (1) CA2268450C (de)
DE (1) DE69735090T2 (de)
DK (1) DK0930883T3 (de)
ES (1) ES2257768T3 (de)
IL (1) IL129475A0 (de)
NZ (1) NZ335291A (de)
WO (1) WO1998017278A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268450C (en) 1996-10-21 2008-08-05 Allelix Biopharmaceuticals, Inc. Neurotrophin antagonist compositions
SK7012001A3 (en) * 1998-11-25 2001-11-06 Merck Patent Gmbh Substituted benzo[de]isoquinoline-1,3-diones
CA2352045A1 (en) * 1998-11-25 2000-06-08 Merck Patent Gesellschaft Mit Beschraenkter Haftung Substituted benzo[de]isoquinoline-1,3-diones
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
US6492380B1 (en) * 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
MXPA05003502A (es) 2002-10-08 2005-09-30 Rinat Neuroscience Corp Metodo para tratar dolor post-quirurgico al administrar un antagonista del factor de crecimiento de nervios y composiciones que contienen el mismo.
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
NZ540730A (en) 2002-12-24 2010-09-30 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ATE491444T1 (de) 2003-02-19 2011-01-15 Rinat Neuroscience Corp Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
KR101504729B1 (ko) 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물
GB0419850D0 (en) * 2004-09-07 2004-10-13 Angeletti P Ist Richerche Bio Therapeutic agents
KR20080058403A (ko) * 2005-09-15 2008-06-25 페인셉터 파마 코포레이션 뉴로트로핀 매개 활성 조절 방법
WO2009039635A1 (en) * 2007-09-24 2009-04-02 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
RS63063B1 (sr) 2010-08-19 2022-04-29 Zoetis Belgium S A Anti-ngf antitela i njihova upotreba
EP2606894A1 (de) 2011-12-20 2013-06-26 Sanofi Neuartige therapeutische Verwendung von p75-Rezeptorantagonisten
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
AU2019234213A1 (en) 2018-03-12 2020-09-03 Zoetis Services Llc Anti-NGF antibodies and methods thereof
WO2023212596A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US627129A (en) * 1899-06-20 Collar-edge-ironing machine
US525841A (en) * 1894-09-11 Baling-press
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications
US4006238A (en) * 1975-08-28 1977-02-01 E. R. Squibb & Sons, Inc. Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents
ES459497A1 (es) * 1977-06-04 1978-04-16 Made Labor Sa Un metodo para la preparacion industrial de naftalimidas y sus derivados.
US4254109A (en) * 1979-11-08 1981-03-03 Ayerst, Mckenna & Harrison Inc. 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives
RU2051677C1 (ru) * 1982-02-10 1996-01-10 Украинский научно-исследовательский институт эндокринологии и обмена веществ Средство для профилактики и лечения диабетических осложнений, ангиопатий, нейропатий, катаракты
US5183821A (en) * 1983-09-19 1993-02-02 Laboratories Knoll, S.A. Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors
IT1214618B (it) * 1985-06-27 1990-01-18 I P A International Pharmaceut Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche.
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
DE3707652A1 (de) * 1987-03-10 1988-09-22 Knoll Ag Verwendung von benzo(de)isochinolin-1,3-dionen zur herstellung von arzneimitteln
DE3707651A1 (de) * 1987-03-10 1988-09-22 Knoll Ag Bis-naphthalimide, ihre herstellung und verwendung
US5420137A (en) * 1989-07-11 1995-05-30 Knoll Ag Amonafide salts
US5356906A (en) * 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
CA2030129A1 (en) * 1989-11-29 1991-05-30 Thomas Saupe 1,8-napthalenedicarboximides as antidotes
US5342942A (en) * 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
DE4232739A1 (de) * 1992-09-30 1994-03-31 Knoll Ag Neue asymmetrisch substituierte bis-Naphthalimide
IL110460A (en) * 1993-08-18 2001-01-11 Basf Ag Bite-naphthalimides, their preparation and pharmaceutical preparations containing them
US6291247B1 (en) * 1994-05-11 2001-09-18 Queen's University At Kingston Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
GB9616105D0 (en) * 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
CA2268450C (en) 1996-10-21 2008-08-05 Allelix Biopharmaceuticals, Inc. Neurotrophin antagonist compositions
CA2279331C (en) 1997-02-07 2010-04-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1998052919A1 (fr) 1997-05-21 1998-11-26 Japan Tobacco Inc. Derives de phtalimide et produit pharmaceutique contenant ces derives
WO2000000472A1 (en) 1998-06-30 2000-01-06 Du Pont Pharmaceuticals Company 5-ht7 receptor antagonists
KR100364205B1 (ko) * 1998-07-03 2002-12-11 다이호야쿠힌고교 가부시키가이샤 나프탈이미도벤즈아미드 유도체 또는 그의 염
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
US6492380B1 (en) * 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding

Also Published As

Publication number Publication date
US20020169182A1 (en) 2002-11-14
IL129475A0 (en) 2000-02-29
EP0930883A1 (de) 1999-07-28
WO1998017278A1 (en) 1998-04-30
EP0930883B1 (de) 2006-01-11
DE69735090T2 (de) 2006-09-14
JP2001503397A (ja) 2001-03-13
US7291629B2 (en) 2007-11-06
AU728523C (en) 2001-08-09
CA2268450A1 (en) 1998-04-30
AU728523B2 (en) 2001-01-11
AU4696897A (en) 1998-05-15
US20080287484A1 (en) 2008-11-20
US20090215815A1 (en) 2009-08-27
ATE315397T1 (de) 2006-02-15
ES2257768T3 (es) 2006-08-01
KR20000052691A (ko) 2000-08-25
CA2268450C (en) 2008-08-05
NZ335291A (en) 2001-02-23
BR9712424A (pt) 2001-11-20
US20050250807A1 (en) 2005-11-10
DK0930883T3 (da) 2006-05-22

Similar Documents

Publication Publication Date Title
DE69735090D1 (de) Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer'schen krankheit und schmerzen
DE69531502D1 (de) Monoamid, diamid, thiol enthaltende metall-chelatierende verbindungen
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
HK1094191A1 (en) Phenyl-carboxamide compounds useful for treating pain
DE69727956D1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
DK0652005T3 (da) Fremgangsmåder til inhibering af endometriose
WO2005056524A3 (en) Therapeutic agents useful for treating pain
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
CA2174544A1 (en) Method for using pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenyl-amino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines as adrenergic agents
DE69431035D1 (de) 2-Phenyl-3-Azoylbenzothiophene zur Erhöhung der Thrombomodulin Expression
GEP20012389B (en) Benzoxazinone Dopamine D4 Receptor Antagonists, Pharmaceutical Composition Containing the Same and Method for Treatment of Psychosis or Schizophrenia
DE69315836D1 (de) Pyrazolpyridine für die behandlung der anämie
IL115617A0 (en) Pharmaceutical composition for prophylaxis and treatment of type i allergic diseases
IL148196A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
NZ503027A (en) Use of rifamycin derivative for treating mastitis in a domestic animal
ATE205843T1 (de) Heterocyclische verbindungen zur behandlung von neurogener entzündung
DE69810332D1 (de) Antibakterielle carbapeneme, zusammensetzungen und verfahren zur behandlung
AU5270696A (en) Novel heterocyclic compounds
ATE220544T1 (de) Neue verwendung von pyrazolopyridinverbindungen
RU97104066A (ru) Сочетание ингибиторов вич-протеазы
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee